Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial

Vesna Brglez, Sonia Boyer-Suavet, Kévin Zorzi, Céline Fernandez, Eric Fontas, Vincent Esnault, Barbara Seitz-Polski, Vesna Brglez, Sonia Boyer-Suavet, Kévin Zorzi, Céline Fernandez, Eric Fontas, Vincent Esnault, Barbara Seitz-Polski

Abstract

Background: Membranous Nephropathy (MN) is a rare autoimmune disease related to PLA2R1 antibodies in 70% of cases. One third of patients enter in spontaneous remission. PLA2R1 epitopes in MN have been characterized in four different domains of PLA2R1 and a mechanism of epitope spreading from the immunodominant CysR domain to CTLD1 and/or CTLD7 and/or CTLD8 domains has been associated with poor prognosis. Epitope spreading could predict spontaneous remission (45% in non-spreader patients vs. 0.05% in spreader patients). The comparison of different regimens of rituximab dosing showed that: (i) early remission rate depends on rituximab dosing, (ii) low dose could be enough for patients with anti-PLA2R1 activity restricted to CysR, (iii) high dose may be required for spreader patients. This study aims to evaluate the efficacy of personalized treatment in PLA2R1-related MN depending on the epitope spreading status, in comparison to the established GEMRITUX protocol. Methods: A multicenter, randomized, controlled, prospective clinical trial will be conducted in 22 French hospitals. Sixty-four consecutive patients with PLA2R1-related MN will be randomly assigned to either the control group following the GEMRITUX protocol (symptomatic treatment for 6 months, if the nephrotic syndrome (NS) persists at month-6, two 375 mg/m2 rituximab infusions at 1 week interval) or the personalized treatment group (patients with no epitope spreading at month-0 will be treated with symptomatic treatment for 6 months, if NS persists at month-6, two 375 mg/m2 rituximab infusions at 1 week interval; patients with epitope spreading at month-0 or month-6 with persistent NS will be treated immediately with two 1 g rituximab infusions at 2 week interval). The primary study outcome is the rate of clinical remission at month-12. The secondary outcomes include complete and partial remissions, immunological remissions, relapses, proteinuria, albuminuria, serum creatinine, eGFR, PLA2R1 antibody titers, severe infections, lymphocyte counts and lymphocyte phenotype, residual rituximab levels at month-3 and neutralizing anti-rituximab antibodies at month-6 and month-12 after rituximab treatment. Discussion: The results of this trial will confirm whether personalized treatment of PLA2R1-driven nephrotic MN is more efficient to induce clinical remission than the established GEMRITUX protocol, and may thus contribute to improved remission rates and reduced relapse rates. Trial registration: NCT03804359 trial number. Registered on 15th January 2019.

Keywords: PLA2R1; epitope spreading; membranous nephropathy; personalized treatment; randomized prospective trial; rituximab.

Copyright © 2020 Brglez, Boyer-Suavet, Zorzi, Fernandez, Fontas, Esnault and Seitz-Polski.

Figures

Figure 1
Figure 1
Detailed overview of the PMMN study protocol. A, active disease; eGFR, estimate glomerular filtration rate; MN, membranous nephropathy; NIAT, Non immunosuppressive antiproteinuric treatment; PLA2R1-Ab, antibodies for phospholipase A2 receptor: R, remission; RTX, rituximab; S-, CysR-restricted activity; S+, CTLD1/7 activity.

References

    1. Lassalle M, Ayav C, Frimat L, Jacquelinet C, Couchoud C. The essential of 2012 results from the French renal epidemiology and information network (REIN) ESRD registry. Nephrol Ther. (2015) 11:78–87. 10.1016/j.nephro.2014.08.002
    1. Simon P, Ramée MP, Autuly V, Laruelle E, Charasse C, Cam G, et al. . Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. Kidney Int. (1994) 46:1192–8. 10.1038/ki.1994.384
    1. Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis. (2010) 56:157–67. 10.1053/j.ajkd.2010.01.008
    1. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, et al. . Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. (1993) 329:1753–9. 10.1056/NEJM199307083290203
    1. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. (2003) 23:324–32. 10.1016/S0270-9295(03)00049-4
    1. Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, et al. . Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. (2002) 346:2053–60. 10.1056/NEJMoa012895
    1. Beck LHJ, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. (2009) 361:11–21. 10.1056/NEJMoa0810457
    1. Tomas NM, Beck LH, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. . Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. (2014) 371:2277–87. 10.1056/NEJMoa1409354
    1. Sethi S, Debiec H, Madden B, Charlesworth MC, Morelle J, Gross L, et al. . Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. (2020) 97:163–74. 10.1016/j.kint.2019.09.014
    1. Lateb M, Ouahmi H, Payré C, Brglez V, Zorzi K, Dolla G, et al. . Anti-PLA2R1 antibodies containing sera induce in vitro cytotoxicity mediated by complement activation. J Immunol Res. (2019) 2019:1324804. 10.1155/2019/1324804
    1. Beck LH, Fervenza FC, Beck DM, Bonegio RGB, Malik FA, Erickson SB, et al. . Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. (2011) 22:1543–50. 10.1681/ASN.2010111125
    1. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. (2015) 385:1983–92. 10.1016/S0140-6736(15)60731-0
    1. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, et al. . Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. (2013) 83:940–8. 10.1038/ki.2012.486
    1. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RAK. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. (2014) 25:1357–66. 10.1681/ASN.2013040430
    1. Ancian P, Lambeau G, Mattei MG, Lazdunski M. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J Biol Chem. (1995) 270:8963–70. 10.1074/jbc.270.15.8963
    1. Fresquet M, Jowitt TA, Gummadova J, Collins R, O'Cualain R, McKenzie EA, et al. . Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol. (2014) 26:302–13. 10.1681/ASN.2014050502
    1. Kao L, Lam V, Waldman M, Glassock RJ, Zhu Q. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol. (2014) 26:291–301. 10.1681/ASN.2013121315
    1. Seitz-Polski B, Dolla G, Payré C, Girard C, Polidori J, Zorzi K, et al. . Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy. J Am Soc Nephrol. (2016) 27:1517–33. 10.1681/ASN.2014111061
    1. Reinhard L, Zahner G, Menzel S, Koch-Nolte F, Stahl RAK, Hoxha E. Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy. J Am Soc Nephrol. (2020) 31:197–207. 10.1681/ASN.2019030273
    1. Seitz-Polski B, Debiec H, Rousseau A, Dahan K, Zaghrini C, Payré C, et al. . Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J Am Soc Nephrol. (2018) 29:401–8. 10.1681/ASN.2017070734
    1. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)-application to the individual patient. Kidney Int. (2012) 82:840–56. 10.1038/ki.2012.280
    1. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. (2002) 360:923–4. 10.1016/S0140-6736(02)11042-7
    1. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, et al. . Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. (2008) 73:117–25. 10.1038/sj.ki.5002628
    1. Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al. . Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J Am Soc Nephrol. (2016) 28:348–58. 10.1681/ASN.2016040449
    1. Cattran D, Brenchley P. Membranous nephropathy: thinking through the therapeutic options. Nephrol Dial Transplant. (2017) 32:i22–9. 10.1093/ndt/gfw404
    1. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. (2007) 2:932–7. 10.2215/CJN.01180307
    1. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, et al. . Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. (2010) 5:2188–98. 10.2215/CJN.05080610
    1. Piro LD, White CA, Janakiraman N, Saven A, Beck TM, Varns C, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. (1999) 10:655–61. 10.1023/A:1008389119525
    1. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. (2007) 62:43–52. 10.1016/j.critrevonc.2006.09.004
    1. Cartron G, Trappe RU, Solal-Céligny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res. (2011) 17:19–30. 10.1158/1078-0432.CCR-10-1292
    1. Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, et al. . Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. (2010) 69:409–12. 10.1136/ard.2009.109041
    1. Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, et al. . Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transplant. (2019) 34:1423–5. 10.1093/ndt/gfz041
    1. Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, et al. . High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol. (2019) 14:1173–82. 10.2215/CJN.11791018
    1. Boyer-Suavet S, Andreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, et al. . Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab. Front Immunol. (2020) 10:3069. 10.3389/fimmu.2019.03069
    1. Beck LH, Salant DJ. Refining our understanding of the PLA2R-antibody response in primary membranous nephropathy: looking forward, looking back. J Am Soc Nephrol. (2020) 31:8–11. 10.1681/ASN.2019111195
    1. Burbelo PD, Joshi M, Chaturvedi A, Little DJ, Thurlow JS, Waldman M, et al. . Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy. J Am Soc Nephrol. (2020) 31:208–17. 10.1681/ASN.2019050538

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться